Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit

MIAMI, Jan. 23, 2013 /PRNewswire/ -- Fuisz Pharma LLC announced today that it has received a notice of allowance from the United States Patent and Trademark Office in connection with its utility patent application entitled "Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit" (US 20120141545).  The allowed claims cover Fuisz Pharma's new tablet and caplet designs for improved transit, including the tablet that Fuisz Pharma calls the "Saturn™".  The Saturn™ has been demonstrated through in vitro tests and in vivo clinical trials to enable easier swallowing and more reliable, faster esophageal clearance as compared with conventional tablet shapes.  A photo of the Saturn™ is included below.

(Photo: http://photos.prnewswire.com/prnh/20130123/PH46501)

Joseph Fuisz, Managing Member, stated, "This allowance of patent claims around our Saturn™ tablet has important therapeutic and commercial implications."

The Saturn™ tablet offers a great benefit through its faster and more reliable esophageal transit.   The high frequency of esophageal transit failure is increasingly understood.  Moreover, the breadth of drug classes that provoke esophageal irritation is increasingly understood to extend far beyond the bisphosphonates as is manifest from the FDA's adverse event reporting system, including cox-2, statins and NSAIDs.  Moreover, esophageal transit failure results in delayed C(max) – with one published study showing C(max) in supine patients with an average C(max) delay of seventy minutes.

Importantly for Fuisz Pharma, the FDA is increasingly recognizing the role of tablet shape in esophageal transit with a view towards requiring generics to follow the size and shape of the reference, branded product.

This patent allowance and the underlying invention can enable a therapeutically superior product with robust, fresh patent protection.  Yet, the adoption of Saturn™ will generally require no formulation change and offers a concise, clear regulatory path (through post approval supplement 21 CFR 314.70 and 314.71).  The Saturn™ is simply made using a new tablet die which Fuisz has already vetted.  Thus, the Saturn™ offers a compelling proposition for industry adoption."

Dr. Richard Fuisz, Founding Member of Fuisz Pharma (http://en.wikipedia.org/wiki/Richard_Fuisz), commented, "I am personally very proud, with my son Joseph, of this invention. There are many reasons for that pride. Firstly, the product makes possible a dramatic improvement in health care. You must get the dosage unit to its effective site in order to get proper blood levels. The most sophisticated pharmacology and the most sophisticated analytical methods, are meaningless if the drug does not pass to its absorptive site.  Secondly, at age 73, I am proud to once again prove that it is the focus and perseverance of the individual that makes progress. Often forgotten in an era when success is, too often by the younger generation, thought to be synonymous with big venture capital and large, filled parking lots. If you are a small inventor reading this: take heart, you may well have the advantage."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.  Fuisz Pharma is also active in diagnostic systems.  Fuisz Pharma has its headquarters in Miami and is not affiliated with MonoSol Rx. www.fuisz.com.

SOURCE Fuisz Pharma LLC

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
These days attacks are becoming more sophisticated and more common. Mobile devices, cloud computing and the Internet of Things have increased the number of access points that must be secured. To complicate matters, CISOs are been directed to secure system without compromising the seaml...
There's an impulse to roll one's eyes and think of legacy applications as problematic, almost by definition. They're old, and they may run on hardware that's slower or more difficult to maintain. But in many instances, that's too simplistic an assessment. Would you respond the same way...
While marketing automation by itself is extremely powerful and is mostly based in the cloud, the effectiveness of such strategies can be enhanced by leveraging the benefits that cloud computing offers. Not too long ago, marketers had to inevitably choose between two options - keep mark...
My daughter is taking a class on entrepreneurship in her senior year of high school (yep, that’s the Silicon Valley for you). She loves the class, the energy of the teacher, and the creativity associated with the subject. As a result, we have had several conversations about what does i...
The origins of SAP GRC software goes back decades, but adoption has been slow. But with the rigor of modern compliance regimes like SOX, coupled with the sheer volume and complexity of online transactions, there’s been an accelerating movement away from document-centric review processe...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE